Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Defibrotide for severe COVID-19 with acute respiratory failure and elevated D-dimer
MOH_2020-06-24_009054Phase 2Not yet recruiting
- Sponsor
- ד"ר מאיר פרייס
- Start
- Jun 2020
- Modality
- Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of defibrotide in coronavirus disease 2019 (COVID-19), sponsored by ד"ר מאיר פרייס. Planned start Jun 2020; status: not yet recruiting.
02
Drugs
defibrotide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on MOH_2020-06-24_009054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-06-24_009054.